Wogenzym® in the Treatment of Patients with Juvenile Chronic Arthritis.
Shaivok A.V., Movsisyan G.R., Stolyarova A.V. Wogenzym(R) in teh Treatment of Patients with Juvenile Chronic Arthritis. INt. J. Immunotherapy XIII(3/4) 93-96 (1997).
Summary:
Ten children (five boys and five girls, aged 2 through 15) suffering
from definite juvenile chronic arthritis (JCA) were enrolled in the
study. All patients received oral Wobenzym® in an open
six-month trial. Articular signs and extra-articular manifestations
improved in the majority of the children. The experimental drug
revealed its therapeutic potential beginning with 4-5 months of
treatment. Enzyme therapy appears to be able to limit the use of
corticosteroids in some JCA patients. No side effects were observed.
Only two children experienced a relapse in the more than 2 years of
follow-up examinations.